Translational Gerontology Branch, Biomedical Research Center, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, 21224, USA; Cardiovascular and Metabolic Diseases Group, Fundació Institut d'Investigació Sanitària Illes Balears (IdISBa), Palma de Mallorca, Spain.
Translational Gerontology Branch, Biomedical Research Center, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, 21224, USA; Nutritional Interventions Group, Precision Nutrition and Aging, Madrid Institute for Advanced Studies - IMDEA Food, CEI UAM+CSIC, Madrid, Spain.
Ageing Res Rev. 2020 May;59:101037. doi: 10.1016/j.arr.2020.101037. Epub 2020 Feb 25.
Aging is a modifiable risk factor for most chronic diseases and an inevitable process in humans. The development of pharmacological interventions aimed at delaying or preventing the onset of chronic conditions and other age-related diseases has been at the forefront of the aging field. Preclinical findings have demonstrated that species, sex and strain confer significant heterogeneity on reaching the desired health- and lifespan-promoting pharmacological responses in model organisms. Translating the safety and efficacy of these interventions to humans and the lack of reliable biomarkers that serve as predictors of health outcomes remain a challenge. Here, we will survey current pharmacological interventions that promote lifespan extension and/or increased healthspan in animals and humans, and review the various anti-aging interventions selected for inclusion in the NIA's Interventions Testing Program as well as the ClinicalTrials.gov database that target aging or age-related diseases in humans.
衰老是大多数慢性疾病的可改变风险因素,也是人类不可避免的过程。开发旨在延缓或预防慢性疾病和其他与年龄相关疾病发作的药物干预措施一直是衰老领域的前沿。临床前研究结果表明,物种、性别和品系在达到理想的促进健康和延长寿命的药物反应方面表现出显著的异质性。将这些干预措施的安全性和有效性转化为人类,以及缺乏可靠的生物标志物来预测健康结果仍然是一个挑战。在这里,我们将调查目前在动物和人类中促进寿命延长和/或增加健康寿命的药物干预措施,并回顾 NIA 干预测试计划中选择的各种抗衰老干预措施,以及 ClinicalTrials.gov 数据库中针对人类衰老或与年龄相关疾病的干预措施。